整合脂质代谢和免疫相关基因的急性髓系白血病新型预后分类（表3）

数据集获取（Figshare）

• 源站标题：Table_3_A novel prognostic classification integrating lipid metabolism and immune co-related genes in acute myeloid leukemia.xlsx
• DOI：10.3389/fimmu.2023.1290968.s007
• 发布日期：2023-11-10
• 文件数：1 个
• 文件总体积：29.74 KB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/Table_3_A_novel_prognostic_classification_integrating_lipid_metabolism_and_immune_co-related_genes_in_acute_myeloid_leukemia_xlsx/24540202

命令行下载

curl -L -o "Table_3_A novel prognostic classification integrating lipid metabolism and immune co-related genes in acute myeloid leukemia.xlsx" "https://ndownloader.figshare.com/files/43103935"

文件清单

• Table_3_A novel prognostic classification integrating lipid metabolism and immune co-related genes in acute myeloid leukemia.xlsx（29.74 KB）

文件总体积 29.74 KB（源站 API 实测）。

数据说明

BackgroundAs a severe hematological malignancy in adults, acute myeloid leukemia (AML) is characterized by high heterogeneity and complexity. Emerging evidence highlights the importance of the tumor immune microenvironment and lipid metabolism in cancer progression. In this study, we comprehensively evaluated the expression profiles of genes related to lipid metabolism and immune modifications to develop a prognostic risk signature for AML.
MethodsFirst, we extracted the mRNA expression profiles of bone marrow samples from an AML cohort from The Cancer Genome Atlas database and employed Cox regression analysis to select prognostic hub genes associated with lipid metabolism and immunity. We then constructed a prognostic signature with hub genes significantly related to survival and validated the stability and robustness of the prognostic signature using three external datasets. Gene Set Enrichment Analysis was implemented to explore the underlying biological pathways related to the risk signature. Finally, the correlation between signature, immunity, and drug sensitivity was explored.
ResultsEight genes were identified from the analysis and verified in the clinical samples, including APOBEC3C, MSMO1, ATP13A2, SMPDL3B, PLA2G4A, TNFSF15, IL2RA, and HGF, to develop a risk-scoring model that effectively stratified patients with AML into low- and high-risk groups, demonstrating significant differences in survival time. The risk signature was negatively related to immune cell infiltration. Samples with AML in the low-risk group, as defined by the risk signature, were more likely to be responsive to immunotherapy, whereas those at high risk responded better to specific targeted drugs.
ConclusionsThis study reveals the significant role of lipid metabolism- and immune-related genes in prognosis and demonstrated the utility of these signature genes as reliable bioinformatic indicators for predicting survival in patients with AML. The risk-scoring model based on these prognostic signature genes holds promise as a valuable tool for individualized treatment decision-making, providing valuable insights for improving patient prognosis and treatment outcomes in AML.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fimmu.2023.1290968.s007（source: https://frontiersin.figshare.com/articles/dataset/Table_3_A_novel_prognostic_classification_integrating_lipid_metabolism_and_immune_co-related_genes_in_acute_myeloid_leukemia_xlsx/24540202）。